Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Barry S. Rodgers-Gray, John R. Fullarton, Xavier Carbonell-Estrany, Ian P. Keary, Jean-Éric Tarride & Bosco A. Paes. (2023) Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics 26:1, pages 630-643.
Read now
Read now
Bosco Paes, John R. Fullarton, Barry S. Rodgers-Gray & Xavier Carbonell-Estrany. (2021) Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Current Medical Research and Opinion 37:7, pages 1149-1153.
Read now
Read now
J.M. Hussman, K.L. Lanctôt & B. Paes. (2013) The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. Journal of Medical Economics 16:1, pages 115-124.
Read now
Read now
Julia M Hussman, Abby Li, Bosco Paes & Krista L Lanctôt. (2012) A review of cost–effectiveness of palivizumab for respiratory syncytial virus. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 553-567.
Read now
Read now
Articles from other publishers (13)
Ian P. Keary, Roberto Ravasio, John R. Fullarton, Paolo Manzoni, Marcello Lanari, Bosco A. Paes, Xavier Carbonell-Estrany, Eugenio Baraldi, Jean-Éric Tarride & Barry Rodgers-Gray. (2023) A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLOS ONE 18:8, pages e0289828.
Crossref
Crossref
Marianne Bracht, Barry Rodgers-Gray, Fabiana Bacchini & Bosco A. Paes. (2023) Understanding Policy Decisions and Their Implications Regarding Preventive Interventions for Respiratory Syncytial Virus (RSV) Infection in Canadian Infants: A Primer for Nurses. Neonatal Network 42:5, pages 291-302.
Crossref
Crossref
Nisha Thampi, Braden D. Knight, Kednapa Thavorn, Richard J. Webster, Krista Lanctot, Steven Hawken & J. Dayre McNally. (2021) Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study. CMAJ Open 9:4, pages E948-E956.
Crossref
Crossref
Marianne Bracht, Fabiana Bacchini & Bosco Paes. (2021) A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants. Neonatal Network 40:1, pages 14-24.
Crossref
Crossref
Jesse Papenburg, Mahwesh Saleem, Johannes Teselink, Abby Li, Georges Caouette, Édith MasséKrista L. Lanctôt. (2020) Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec. Pediatric Infectious Disease Journal 39:8, pages 694-699.
Crossref
Crossref
Sudipta Das, Claudette St. Croix, Misty Good, Jie Chen, Jinming Zhao, Sanmei Hu, Mark Ross, Michael M. Myerburg, Joseph M. Pilewski, John Williams, Sally E. Wenzel, Jay K. Kolls, Anuradha Ray & Prabir Ray. (2020) Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy. iScience 23:7, pages 101256.
Crossref
Crossref
Stephen MacAmanda SumnerSamuel Duchesne-BelangerRobert StirlingMatthew TunisBeate Sander. (2019) Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143:5.
Crossref
Crossref
Sudipta Das, Mahesh Raundhal, Jie Chen, Timothy B. Oriss, Rachael Huff, John V. Williams, Anuradha Ray & Prabir Ray. (2017) Respiratory syncytial virus infection of newborn CX3CR1-deficent mice induces a pathogenic pulmonary innate immune response. JCI Insight 2:17.
Crossref
Crossref
Mitchell Goldstein, Raylene Philips, John DeVincenzo, Leonard Krilov, T. Allen Merritt, Ram Yogev, Suzanne Staebler, Munaf Kadri, Jaimie Fergie, Michael Schechter, Millicent Gorham & James Cherry. (2017) National Perinatal Association 2018 Respiratory Syncytial Virus (RSV) Prevention Clinical Practice Guideline: An Evidence-Based Interdisciplinary Collaboration. Neonatology Today 12:10, pages 1-14.
Crossref
Crossref
Andrew HiattNatasha BohorovaOgnian BohorovCharles GoodmanDo KimMichael H. PaulyJesus VelascoKevin J. WhaleyPedro A. Piedra, Brian E. Gilbert & Larry Zeitlin. (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences 111:16, pages 5992-5997.
Crossref
Crossref
Tea Andabaka, Jason W Nickerson, Maria Ximena Rojas-Reyes, Juan David Rueda, Vesna Bacic Vrca & Bruno Barsic. (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Evidence-Based Child Health: A Cochrane Review Journal 8:6, pages 2243-2376.
Crossref
Crossref
Tea Andabaka, Jason W Nickerson, Maria Ximena Rojas-Reyes, Juan David Rueda, Vesna Bacic Vrca & Bruno Barsic. (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Amanda Burls & Josie Sandercock. (2011) Decision-making under conditions of uncertainty-what can we learn from palivizumab?. Acta Paediatrica 100:10, pages 1302-1305.
Crossref
Crossref